Tilray Inc (TLRY)
$18.20 0.35 (1.89%)
19:43 EST TLRY Stock Quote Delayed 15 Minutes
Previous Close $18.20
Market Cap -
PE Ratio -
Volume (Avg. Vol.) 1.24M
Day's Range 18.07 - 18.88
52-Week Range 18.00 - 106.00
Dividend & Yield N/A (N/A)
TLRY Stock Predictions, Articles, and Tilray Inc News
- From InvestorPlace
- From the Web
Tilray stock tumbles as investors demand profitability. Tilray, like other cannabis stocks, is stuck in a death spiral as long as the copmany can't produce profits.
Tilray stock keeps falling and now is nearing its IPO price. Trading in TLRY stock shows how much faith investors have lost in pot stocks.
It’s been absolutely grueling for Tilray stock. It seems like nothing can help shares. But interestingly enough, this may be setting up a good entry point for TLRY.
Revised earnings guidance for Hexo spooked the market and hit cannabis stocks, with Tilray stock closing down 13.5% on Thursday.
If understood and used correctly, technical analysis of marijuana stocks can allow you to identify important levels and trends -- and profit.
Tilray stock's 52-week high is just under $179. On Friday, Oct. 4, the shares barely closed above $24. The outlook for Tilray and some of its marijuana rivals will improve at some point. Knowing when that point will arrive, well, that's a different ballgame. Over the near-term, things are problematic for Tilray stock because losses are accelerating. Over the past month, the shares are lower by 25% and the loss of the past quarter is almost double that.
Opportunities abound for Tilray stock but the cannabis infrastructure still needs to be built out, along with more favorable legalization momentum. For now, TLRY is interesting, but it will require patience from investors.
By Thomas Niel
The company has several catalysts in play, but nothing unique compared to what other cannabis companies are doing. I remain on the fence with pot stocks in general. But if I were entering a position today, I would choose something like Hexo or Aphria to place my bet on the legalized marijuana story. I suggest you do the same. Look elsewhere for a pot play, but steer clear of TLRY stock.
Each of these seven marijuana stocks can teach a valuable lesson into how to use technical analysis to identify important levels.
By David Moadel
The SAFE Banking Act might not pass the Senate, but that doesn't mean you can't buy TLRY stock.
Tilray stock has been beaten to a pulp, like most other pot stocks. But, there's a nuance here that could readily reignite TLRY shares.
This has been a tough year for cannabis stocks, and ACB stock continues to slump two weeks after it was hammered by Q4 earnings.
As Tilray CEO Brendan Kennedy stated in its Q2 2019 press release, the company nearly doubled its adult-use revenue in the quarter.
Cannabis stocks are in a bear phase and it is taking CGC stock down with it. Beyond next year, profits are around the corner.
The downtrend of Tilray stock has serious momentum, and it's best to avoid stepping in the way of this downward pressure on TLRY for now.
Once a high-flying cannabis player, Tilray stock has floundered along with the rest of the industry. But having recently found a bottom, speculators may be tempted to bet on TLRY’s long shot but viable narratives.
Will Tilray's growth strategy lead to a new bull market in the stock? Or is it time to sell Tilray stock on its recent bounce?
Throughout this year, marijuana-related investments like Aurora Cannabis stock took a massive beating. Still, markets work in cycles and with ACB not dropping to new lows, it suggests a possible turnaround is coming with the right catalyst.
Stepping into Aphria stock now is a little bit like catching a falling knife. Just wait for it to hit the floor.
Shares of Canopy Growth stock have been struggling immensely over the last few months. However, CGC has some new momentum.
From Talk Markets
Navellier RatingsPowered by Portfolio Grader